ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Volume : 25 Issue : 9 Year : 2021
Quick Search



Prostanoids in the treatment of pulmonary arterial hypertension [Anatol J Cardiol]
Anatol J Cardiol. 2010; 10(Suppl 2): 2-8 | DOI: 10.5152/akd.2010.123

Prostanoids in the treatment of pulmonary arterial hypertension

Murat Başkurt1, M. Serdar Küçükoğlu2
1Institute of Cardiology, Istanbul University, İstanbul
2İstanbul Üniversitesi Kardiyoloji Enstitüsü, Kardiyoloji Anabilim Dalı, İstanbul, Türkiye

Prostacyclin, endothelin-1, and nitric oxide pathways are involved in the pathogenesis of pulmonary arterial hypertension. This devastating disease of the pulmonary vasculature is associated with vasoconstriction, thrombosis and proliferation, and this may be partly due to lack of endogenous prostacyclin secondary to prostacyclin synthase downregulation. Prostanoids (prostacycin analogues) are potent vasodilators and possess antiaggregant, antiinflammatory and antiproliferative properties. The first agent to be approved for the treatment of pulmonary arterial hypertension was epoprostenol. In the last decade other prostanoids (treprostinil, iloprost) has been approved for the treatment of pulmonary arterial hypertension.

Keywords: Pulmonary arterial hypertension, prostacylin, epoprostenol, treprostonil, iloprost, beraprost

Murat Başkurt, M. Serdar Küçükoğlu. Prostanoids in the treatment of pulmonary arterial hypertension. Anatol J Cardiol. 2010; 10(Suppl 2): 2-8